Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.39 |
| ▸ | COMT | P21964 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CDC7 | O00311 | 5/20 | 0.38 |
| ▸ | DBF4 | Q9UBU7 | 5/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.34 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13935179 | 0.93 | COMT (0.39) | APPCOMTNPC1KDM4ERAB9A | |
| SCHEMBL1609346 | 0.88 | COMT (0.43) | APPCOMTNPC1KDM4ERAB9A | |
| SCHEMBL3815204 | 0.81 | CDC7 (0.33) | APPCOMTNPC1KDM4ERAB9A | |
| SCHEMBL13935177 | 0.81 | CCNE1 (0.34) | APPNPC1KDM4ERAB9ACDC7 | |
| SCHEMBL1608166 | 0.75 | MAPT (0.45) | COMTRAB9A | |
| SCHEMBL8054509 | 0.68 | APP (0.63) | APPNPC1KDM4ERAB9ACDC7 | |
| SCHEMBL13935093 | 0.68 | APP (0.43) | APPCOMTNPC1KDM4ERAB9A | |
| SCHEMBL19757223 | 0.62 | APP (0.52) | APPKDM4ERAB9AMMP2MMP9 | |
| SCHEMBL25026544 | 0.62 | KDM4E (0.67) | APPNPC1KDM4ERAB9A | |
| SCHEMBL11371956 | 0.61 | GPR35 (0.51) | NPC1KDM4ERAB9ACDC7PKN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086852-A2 | PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2011-04-14 | — | — | US | claimed |
| EP-1910325-B1 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORP (FI) | 2010-10-06 | — | — | EP | claimed |
| EP-1910325-A2 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2008-04-16 | — | — | EP | claimed |
| WO-2007010085-A2 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2007-01-25 | — | — | WO | claimed |
| US-8318785-B2 | Pharmaceutical compounds | ORION CORPORATION (FI) | 2012-11-27 | — | — | US | disclosed |
| US-20110086852-A2 | PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2011-04-14 | — | — | US | disclosed |
| EP-1910325-B1 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORP (FI) | 2010-10-06 | — | — | EP | disclosed |
| US-20090209532-A1 | PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2009-08-20 | — | — | US | disclosed |
| EP-1910325-A2 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007010085-A2 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209532-A1 | PHARMACEUTICAL COMPOUNDS | COMT, CYP2C19, UGT1A1 | APP 1344/4885COMT 1/4885NPC1 558/4885 |
| US-20110086852-A2 | PHARMACEUTICAL COMPOUNDS | COMT, CYP2C19, CYP3A4 | APP 1598/4885COMT 1/4885NPC1 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.